

# A small molecule inhibitor of the ubiquitin activating enzyme for regulating p53 in lung cancer

Korea Research Institute of Chemical Technology (KRICT)



ONCOLOGY	Lead						
Product Type	Small molecule						
Indication	1st indication: Non-Small-Cell Lung Cancer						
Target	Ubiquitination pathway: UBA6 (E1) - USE1 (E2)						
MoA(Mechanism of Action)	p53 activate by regulation of ubiquitination pathway, UBA6(E1)-USE1(E2)						
Competitiveness	<table border="1"> <thead> <tr> <th>Drug name</th> <th>Target</th> </tr> </thead> <tbody> <tr> <td>Pevonedistat (MLN4924)</td> <td>NEDD8 Activating Enzyme</td> </tr> <tr> <td>Velcade® (Bortezomib)</td> <td>The 26S proteasome</td> </tr> </tbody> </table>	Drug name	Target	Pevonedistat (MLN4924)	NEDD8 Activating Enzyme	Velcade® (Bortezomib)	The 26S proteasome
	Drug name	Target					
	Pevonedistat (MLN4924)	NEDD8 Activating Enzyme					
Velcade® (Bortezomib)	The 26S proteasome						
Development Stage	Lead						
Route of Administration	Parenteral Subcutaneous						